In the IMpower151 study, a comparable investigator-assessed median PFS was seen between Chinese patients with EGFR/ALK-mutated NSCLC who received ABCP and those who received BCP (8.5 months vs. 8.3 months; HR = 0.86 [95% CI: 0.61–1.21]).37 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.